Table 1 Molecular and cellular genetic alternation of patient at different disease stages
From: Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient
Examination | Before allo-HSCT | After allo-HSCT | |||||
|---|---|---|---|---|---|---|---|
Initial diagnosis | CR1 | Relapse | CR2 | 1 | 2 | 3 | |
Karyotype | t (9; 11) (p21.3;q23.3) | NA | – | NA | – | – | NA |
Fusion | KMT2A-MLLT3 | – | – | NA | – | NA | NA |
Variants (VAF %) | TET2 (25.25) | TET2 (48.33) | TET2 (51.78) | TET2 (49.88) | TET2 (48.58) | TET2 (50.20) | TET2 (52.59) |
WT1 (49.19) | WT1 (50.11) | WT1 (51.87) | WT1 (48.35) | ||||
WT1 level (%) | 0 | NA | 0.03 | 0.15 | NA | NA | 0 |